Jacobio Pharma poised to turn a profit from precision cancer drugs
The Chinese firm is pocketing an upfront payment for a gene-focused drug under development and anticipates rising sales of an approved treatment for lung cancer Key Takeaways: Early clinical data…
RELATED ARTICLES
-
Big deal, bigger doubts: CSPC slides after $18.5 billion pact
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
- Cancer screening company faces tough IPO test as market cools
-
InnoCare hits profit milestone, enters new phase with global expansion, strong pipeline
9969.HK688428.SHG
